Eli Lil­ly keeps its foot on deal­mak­ing ped­al, re­cruit­ing Car­olyn Bertozzi's pro­tein degra­da­tion tech for $1.6B+

4 years ago
Deals

Mod­er­na wraps its BLA for their megablock­buster Covid vac­cine. Chances are you won't have to wait long on the FDA

4 years ago
FDA+

Mer­ck­'s 15-strain pneu­mo­nia shot match­es Pre­vnar 13 in late-stage in­fant study, but Pfiz­er's next-gen shot looms

4 years ago
R&D
Pharma

Alzheimer's biotech comes un­der at­tack as pe­ti­tion calls for tri­al halt, da­ta au­dit — and it's fight­ing back

4 years ago
R&D

Covid-19 roundup: J&J of­fers new da­ta to sup­port boost­ers — but some ex­perts are not im­pressed; Thai­land ...

4 years ago
Coronavirus

Rare dis­ease drug­mak­er files for ap­proval de­spite ob­jec­tions from FDA on ad­e­quate tri­al da­ta

4 years ago
R&D
FDA+

In­side the quixot­ic 30-year quest that gave us the Covid-19 treat­ments, vac­cines and could un­lock vac­ci­nol­o­gy’s new ...

4 years ago
In Focus

An­oth­er Covid-19 an­ti­body cock­tail on the menu? Brii Bio touts ear­ly win in NIH study for a com­bo al­ready used in ...

4 years ago
R&D
Coronavirus

A Bris­tol My­ers-backed biotech wants to treat heart dis­ease with non-cod­ing RNAs. It's one step clos­er to ...

4 years ago
Financing

Im­muno­core's bis­pe­cif­ic lands speedy re­view with FDA, EMA; Low-pro­file gene ther­a­py play­er grabs $30M

4 years ago
News Briefing

Re­gen­eron earns mid-stage win for high­er dose of Eylea, hop­ing to re­fresh its sales pitch

4 years ago
R&D
Pharma

EC ap­proves Ab­b­Vie's upadac­i­tinib as first JAK in­hibitor for atopic der­mati­tis

4 years ago
FDA+

As leader is freed from prison, Sam­sung Bi­o­log­ics nabs mas­sive in­vest­ment from par­ent com­pa­ny's $205B spend­ing spree

4 years ago
Outsourcing
Manufacturing

Covid-19 roundup: Ear­ly Is­rael da­ta show boost­ers may slow Delta; Fau­ci says Pfiz­er/BioN­Tech OK will spur man­dates

4 years ago
Coronavirus

What's Kevin Ju­dice cook­ing up at DiCE now that he's stashed an ex­tra $60M?

4 years ago
Financing

For­mer Blue­print and Pelo­ton vets team up to take on big play­ers in grow­ing hunt for a new type of small mol­e­cule

4 years ago
Financing
Startups

Next user fee deal re­veals where in­dus­try won at the ne­go­ti­at­ing ta­ble with FDA

4 years ago
FDA+

Ex­clu­sive: Roche tees up $3B+ for Shape's RNA edit­ing plat­form, with the bold promise of 'one-time' cures for ...

4 years ago
Deals

No­var­tis' CAR-T fails to help a vul­ner­a­ble group of NHL pa­tients — quash­ing hope of mov­ing up lines of treat­ment

4 years ago
R&D
Cell/Gene Tx

Ver­tex goes back to gene-edit­ing part­ner — and sci­ence founder Feng Zhang — to add $1.2B deal on en­gi­neered cell ...

4 years ago
Deals

Ther­a­vance takes a gut punch as J&J-part­nered JAK drug flops key test in ul­cer­a­tive col­i­tis

4 years ago
R&D

Cara, Vi­for Phar­ma score speedy FDA nod on itch­ing drug for CKD — shares surge

4 years ago
Pharma
FDA+

One of Glax­o­SmithK­line's top can­cer drug prospects goes down in 3rd straight set­back, leav­ing a $4B deal on life ...

4 years ago
R&D

PDU­FA VII: What's new, and what's sig­nif­i­cant in the next user fee deal

4 years ago
FDA+
First page Previous page 658659660661662663664 Next page Last page
A service from the Financial Times